查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854614

血糖监测市场按应用、最终用户、产品类型和分销管道划分－2025-2032年全球预测

Blood Glucose Monitoring Market by Application, End User, Product Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血糖监测市场规模将达到 272.3 亿美元，复合年增长率为 8.59%。

关键市场统计数据
基准年 2024 140.8亿美元
预计年份：2025年 152.7亿美元
预测年份 2032 272.3亿美元
复合年增长率 (%) 8.59%

本书全面而深刻地概述了技术进步、不断演变的护理模式和监管力量如何改变血糖值监测实践和患者预后。

血糖值管理融合了临床疗效、患者自主性和技术创新。过去十年，感测器精度、数据连接性和可穿戴设备人体工学的不断提升，使血糖监测从零散的测量转变为持续的、以洞察为导向的护理。因此，临床医生越来越多地将基于趋势的资讯融入治疗决策，而患者则受益于即时回馈，从而更好地进行自我管理和提高治疗依从性。这种转变影响着初级保健、门诊和专科护理的产品开发、报销策略和诊疗路径。

同时，监管力度和品质标准不断加强，迫使製造商和服务供应商优先考虑互通性、资料隐私和临床检验。医疗保健系统正在调整报销框架，以认可能够实现远端监测和远端医疗的干预措施，从而进一步推动先进监测技术的应用。此外，人口结构和生活方式因素持续推动对妊娠糖尿病管理、小儿科护理和成人慢性病管理解决方案的需求。综上所述，这些发展为寻求透过改善血糖控制结果来创造价值的相关人员创造了一个更复杂但也充满机会的环境。

本执行摘要综合了这些动态，揭示了变革性的结构转变，并为临床领导者、产品团队、支付方和分销合作伙伴在应对不断变化的血糖值监测领域时提出了可操作的建议。

感测器技术的进步、数位化整合和分散式医疗模式如何融合，从而变革血糖监测和临床工作流程

由于技术融合、医疗服务模式的演变以及患者期望的改变，血糖监测领域正在经历显着变化。首先，感测器技术的成熟使其能够支援更长的佩戴时间、在整个血糖值范围内提高测量精度并降低校准要求。因此，临床医生可以长期获得更稳定的数据，从而更好地识别血糖模式并儘早进行干预。同时，数位健康基础设施（包括云端平台、可互通的电子健康记录和安全的患者门户网站）的扩展，使得血糖数据能够无缝地传输临床工作流程，缩短了从测量到临床干预的週期。

此外，医疗服务模式正朝着去中心化方向发展。远端监测、虚拟糖尿病教育和社区计画正在减少对集中式实验室检测的依赖，并促进在门诊和居家照护中早期疗育。这些医疗服务创新与提升病患参与度的改善措施相辅相成，例如简化的设备介面、个人化提醒和游戏化的依从性工具。同时，支付方和监管机构正在调整政策，以支持远端监测和真实世界证据的生成，从而进一步加速这些技术的普及应用。

综上所述，这些转变形成了一个回馈循环：更优质的数据带来更优质的医疗服务，而更完善的医疗模式又推动了对先进监测解决方案的需求。能够协调产品开发、报销策略和临床整合的相关人员，最能掌握价值，并推动血糖控制的持续改善。

2025 年关税变化如何影响血糖监测解决方案的製造和分销的采购、供应弹性和定价策略

关税政策和贸易动态将对医疗设备供应链、零件采购和定价策略产生重大影响。以血糖值监测领域为例，2025年关税的累积变化迫使製造商和经销商重新评估其采购路径，实现供应商多元化，并优化库存策略以降低成本波动风险。企业采取的应对措施包括加快近岸外包和区域采购倡议，以减少跨境关税波动带来的风险，并增强供应链的韧性。因此，采购团队调整了合约结构，纳入了感测器、黏合剂和电子模组等关键零件的替代供应商。

营运调整并未止步于采购环节。物流团队实施了多式联运方案，并增加了区域配送中心的缓衝库存，以确保供应的连续性。这些措施保障了医院、居家照护机构和零售通路的产品供应，同时避免了终端用户面临价格的突然波动。同时，製造商加强了与委託製造和零件供应商的谈判，以分担风险并稳定单位经济效益。

从策略角度来看，关税带来的压力促使商业部门和监管部门加强合作，以简化清关和合规流程。这也凸显了产品设计决策的重要性，即减少对关税敏感型原料的依赖。最终，那些采用敏捷采购、投资区域供应节点并将定价框架与成本转嫁机制结合的企业，能够更有效地应对关税环境，同时在临床和消费管道中维持服务水准。

精准的细分洞察揭示了临床应用案例、终端用户需求、产品系列和通路，从而指导有针对性的策略和创新。

细分市场分析明确了临床需求、支付方关注点和产品创新之间的交汇点，从而能够针对治疗和商业层面製定精准策略。基于应用领域，市场分析涵盖妊娠期糖尿病、1 型糖尿病和 2 型糖尿病，重点关注不同的临床病程和监测需求，从妊娠相关的血糖控製到强化胰岛素治疗和慢性病自我护理。因此，产品需求和教育支援必须进行客製化，以应对短暂的妊娠期状况、终身自体免疫糖尿病管理以及 2 型糖尿病典型的生活方式相关模式。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将连续血糖监测数据与电子健康记录平台整合
  • 利用近红外线技术的非侵入式光学葡萄糖感测器的出现
  • 推出一款基于人工智慧的预测分析工具，用于个人化血糖趋势预测
  • CGM製造商与远端医疗服务供应商之间的伙伴关係在全球范围内不断扩大。
  • 透过远端患者监护扩展基于订阅的血糖监测服务
  • 实施可互通的感测器和胰岛素帮浦通讯标准以实现自动化
  • 开发适用于儿童和老年人、所需样本量较小的血糖感测器

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按应用分類的血糖监测市场

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

9. 按最终用户分類的血糖监测市场

  • 门诊治疗
  • 诊断实验室
  • 居家照护
  • 医院

第十章 依产品类型分類的血糖监测市场

  • 连续血糖监测系统
    • 间歇性扫描系统
    • 即时连续系统
  • 自我监测设备
    • 控制解决方案
    • 血糖值监测仪
    • 穿刺装置
    • 测试条

第十一章 依分销管道分類的血糖监测市场

  • 医院诊所
  • 线上零售商
  • 药局

12. 按地区分類的血糖监测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 依组别分類的血糖监测市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国血糖监测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Roche Diagnostics International AG
    • Abbott Laboratories
    • Dexcom, Inc.
    • LifeScan, Inc.
    • Ascensia Diabetes Care Holdings AG
    • Medtronic plc
    • Becton, Dickinson and Company
    • Nova Biomedical Corporation
    • Nipro Corporation
    • Sinocare, Inc.
Product Code: MRR-957C47F90031

The Blood Glucose Monitoring Market is projected to grow by USD 27.23 billion at a CAGR of 8.59% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 14.08 billion
Estimated Year [2025] USD 15.27 billion
Forecast Year [2032] USD 27.23 billion
CAGR (%) 8.59%

A compelling overview of how technological progress, care model evolution, and regulatory forces are reshaping blood glucose monitoring practice and patient outcomes

The management of blood glucose levels sits at the intersection of clinical outcomes, patient autonomy, and technological innovation. Over the past decade, continuous improvements in sensor accuracy, data connectivity, and wearable ergonomics have elevated monitoring from episodic measurement to sustained, insight-driven care. Consequently, clinicians increasingly integrate trend-based information into therapeutic decisions while patients benefit from real-time feedback that supports self-management and adherence. These shifts have implications for product development, reimbursement strategies, and care pathways across primary, ambulatory, and specialized settings.

In parallel, regulatory scrutiny and quality standards have intensified, prompting manufacturers and service providers to prioritize interoperability, data privacy, and clinical validation. Healthcare systems are adapting reimbursement frameworks to recognize remote monitoring and telehealth-enabled interventions, which further incentivizes adoption of advanced monitoring technologies. At the same time, demographic and lifestyle factors continue to drive demand for solutions that accommodate gestational diabetes management, pediatric care, and adult chronic disease control. Taken together, these developments create a more complex but opportunity-rich environment for stakeholders seeking to deliver value through improved glycemic outcomes.

This executive summary synthesizes those dynamics, highlights transformative structural shifts, and outlines actionable recommendations for clinical leaders, product teams, payers, and distribution partners as they navigate the evolving landscape of blood glucose monitoring.

How sensor advancements, digital integration, and decentralized care models are converging to transform blood glucose monitoring and clinical workflows

The landscape of blood glucose monitoring is undergoing transformative shifts driven by technology convergence, evolving care delivery, and changing patient expectations. First, sensor technology has matured to support longer wear times, improved accuracy across glycemic ranges, and reduced calibration requirements. As a result, clinicians can rely on more consistent longitudinal data, enhancing the ability to identify patterns and intervene earlier. In tandem, the expansion of digital health infrastructure-cloud platforms, interoperable electronic health records, and secure patient portals-has enabled seamless transmission of glucose data into clinical workflows, thereby shortening the loop from measurement to clinical action.

Moreover, care delivery models are moving toward decentralized paradigms. Remote monitoring, virtual diabetes education, and community-based programs are reducing dependence on centralized laboratory testing and facilitating earlier intervention in ambulatory and home-care settings. These delivery innovations are complemented by patient-facing improvements: simplified device interfaces, personalized alerts, and gamified adherence tools that increase engagement and retention. Meanwhile, payers and regulators are adapting policies to support remote monitoring and real-world evidence generation, which further accelerates adoption.

Taken together, these shifts create a feedback loop where better data informs better care, and improved care models increase demand for advanced monitoring solutions. Stakeholders that align product development, reimbursement strategy, and clinical integration will be best positioned to capture value and drive sustained improvements in glycemic management.

How 2025 tariff changes reshaped procurement, supply resilience, and pricing strategies across manufacturing and distribution of blood glucose monitoring solutions

Tariff policy and trade dynamics can materially influence supply chains, component sourcing, and pricing strategies for medical devices. In the context of blood glucose monitoring, cumulative tariff changes in 2025 prompted manufacturers and distributors to reassess procurement pathways, diversify supplier bases, and optimize inventory strategies to mitigate cost volatility. Firms responded by accelerating nearshoring and regional sourcing initiatives to reduce exposure to cross-border tariff fluctuations and to enhance supply resilience. Consequently, procurement teams restructured agreements to include alternative suppliers for critical components such as sensors, adhesives, and electronic modules.

Operational adjustments extended beyond sourcing. Logistics teams implemented multi-modal transportation plans and increased buffer stocks at regional distribution centers to maintain continuity of supply. These tactics preserved product availability for hospitals, home care providers, and retail channels while limiting abrupt price adjustments for end users. At the same time, manufacturers intensified negotiations with contract manufacturers and component vendors to share risk and stabilize unit economics.

From a strategic perspective, tariff-driven pressures encouraged stronger collaboration between commercial and regulatory functions to streamline customs clearance and compliance processes. They also highlighted the importance of product design decisions that reduce reliance on tariff-sensitive inputs. Ultimately, organizations that adopted agile sourcing, invested in regional supply nodes, and aligned pricing frameworks with cost pass-through mechanisms navigated the tariff environment more effectively while sustaining service levels across clinical and consumer channels.

Precision segmentation insights that reveal clinical use cases, end-user demands, product families, and distribution pathways to guide targeted strategies and innovation

Segmentation analysis provides clarity on where clinical demand, payer focus, and product innovation converge, enabling targeted strategies across therapeutic and commercial dimensions. Based on Application, the market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes, which underscores varied clinical trajectories and monitoring needs from pregnancy-related glycemic control to intensive insulin management and chronic disease self-care. As a result, product requirements and educational support must be tailored to accommodate transient gestational conditions, lifelong autoimmune diabetes management, and the lifestyle-related patterns typical of Type 2 Diabetes.

Based on End User, the market is studied across Ambulatory Care, Diagnostic Laboratories, Home Care, and Hospitals, indicating that deployment models differ by care intensity and clinical oversight. Ambulatory and home settings prioritize ease of use, connectivity, and patient education, whereas hospitals and diagnostic laboratories emphasize accuracy, calibration standards, and integration with institutional workflows. This split in end-user needs necessitates differentiated go-to-market approaches and service models to address professional training, procurement cycles, and reimbursement complexity.

Based on Product Type, the market is studied across Continuous Glucose Monitoring Systems and Self Monitoring Devices. The Continuous Glucose Monitoring Systems category is further studied across Intermittently Scanned Systems and Real Time Continuous Systems, reflecting divergence between on-demand scanning solutions and always-on data streams that enable alerts and automated insulin delivery. The Self Monitoring Devices category is further studied across Control Solutions, Glucose Meters, Lancing Devices, and Test Strips, which highlights the breadth of accessory and consumable requirements tied to point-of-care testing. Manufacturers should therefore align R&D, pricing, and lifecycle support with the distinct usage patterns and consumable economics of each product family.

Based on Distribution Channel, the market is studied across Hospitals Clinics, Online Retailers, and Pharmacies, illustrating that accessibility, regulatory compliance, and patient purchasing behaviors vary by channel. Hospitals and clinics center on institutional procurement and clinician preference, pharmacies balance retail demand with professional counseling, and online retailers emphasize convenience, subscription models, and direct-to-consumer fulfillment. Understanding these segmentation layers enables more precise channel strategies and tailored customer engagement that reflect clinical, consumer, and institutional buying drivers.

Regional adoption patterns and healthcare system nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape distribution, reimbursement, and product strategies

Regional dynamics influence adoption patterns, reimbursement frameworks, and competitive positioning across different health systems. In the Americas, health systems span diverse payer models and a dense private provider network, prompting rapid uptake of digital monitoring tools where reimbursement aligns with remote care. This region often leads in direct-to-consumer distribution and sees strong participation from integrated delivery networks that incorporate continuous monitoring into chronic care management programs. Consequently, manufacturers emphasize interoperability with major electronic health records, robust patient support services, and payer engagement strategies to facilitate coverage.

In Europe, Middle East & Africa, the regulatory landscape and procurement practices vary significantly across countries, driving heterogeneous adoption timelines. Western European markets tend to prioritize rigorous clinical validation and structured reimbursement pathways, whereas parts of the Middle East and Africa focus on scalability and affordability. As a result, tailored pricing strategies, public-private partnerships, and localized training initiatives are often necessary to expand access while maintaining clinical standards. Regional distributors play a critical role in navigating regulatory approvals and supply logistics.

Across Asia-Pacific, rapid urbanization, growing private healthcare investment, and rising awareness of chronic diseases have accelerated demand for monitoring technologies. Diverse healthcare infrastructures-ranging from advanced tertiary centers to decentralized primary care-require flexible product portfolios and culturally adapted education programs. Manufacturers frequently pursue strategic alliances and localized manufacturing to meet regulatory requirements and competitive pricing pressures. Taken together, these regional characteristics demand differentiated product roadmaps, channel partnerships, and stakeholder engagement to optimize adoption and impact.

Competitive dynamics and strategic imperatives for device makers, platform providers, and service innovators shaping future leadership in blood glucose monitoring

The competitive landscape features established device manufacturers, specialist sensor developers, software platform providers, and an emerging cohort of integrated care solution vendors. Market leaders focus on driving clinical evidence, improving sensor performance, and expanding ecosystem partnerships that link monitoring data to decision support and therapeutic delivery. Strategic priorities for industry players include enhancing data interoperability, securing regulatory approvals for expanded indications, and building patient support services that increase retention and drive lifetime value.

In this environment, new entrants and technology-focused firms differentiate through niche innovations such as adhesive chemistry improvements, non-invasive sensing research, and advanced analytics that translate raw glucose signals into actionable clinical insights. Partnerships between device companies and digital health platforms facilitate the development of value-added services like medication adherence modules and predictive risk modeling. Meanwhile, contract manufacturers and component suppliers play a pivotal role in scaling production and enabling cost efficiencies.

Competitive positioning increasingly depends on the ability to integrate end-to-end offerings that combine hardware, software, and services. Companies that invest in clinical validation, cultivate payer relationships, and demonstrate real-world outcome improvements will be better placed to secure long-term contracts with health systems and payers. Leaders also prioritize sustainability in design and consumable management to address environmental concerns tied to single-use components and electronic waste.

Actionable cross-functional strategies for manufacturers and healthcare partners to enhance product adoption, supply resilience, and payer-aligned value propositions

Industry leaders should adopt a multifaceted approach that aligns product innovation with clinical integration, payer value, and scalable distribution. First, prioritize interoperability and data governance to ensure devices integrate seamlessly into clinician workflows and meet evolving privacy standards. By doing so, manufacturers will reduce friction during procurement and improve clinician adoption rates. Second, develop differentiated value propositions for distinct clinical applications: solutions for gestational diabetes should emphasize ease of use and maternal-fetal safety, while products targeting Type 1 Diabetes must focus on reliability for intensive insulin management and closed-loop therapy compatibility.

Third, strengthen channel strategies by combining institutional partnerships with direct-to-consumer offerings and subscription models that stabilize lifecycle revenues. Manufacturers should also invest in patient education programs and clinician training to enhance outcomes and minimize device abandonment. Fourth, pursue supply chain resilience through supplier diversification, regional sourcing, and modular design choices that lower exposure to trade policy shifts. Finally, collaborate proactively with payers and health systems to generate real-world evidence that demonstrates clinical and economic value, thereby unlocking reimbursement pathways and facilitating broader adoption.

Implementing these recommendations requires cross-functional coordination between R&D, commercial, regulatory, and clinical teams to translate strategic intent into measurable improvements in access, adherence, and outcomes.

A transparent and rigorous research approach combining peer-reviewed evidence, stakeholder interviews, and comparative device analysis to produce actionable insights

This study synthesizes insights from a combination of secondary sources, primary stakeholder interviews, and systematic device and clinical literature reviews to ensure a robust and transparent methodological foundation. Secondary research included peer-reviewed clinical studies, regulatory filings, device labeling, and technology white papers to capture device performance characteristics and safety profiles. Primary interviews were conducted with clinicians, procurement specialists, payers, and industry executives to validate real-world use cases, procurement behavior, and adoption barriers. These discussions informed qualitative themes around patient engagement, care models, and channel dynamics.

Analytical procedures included comparative device feature mapping, end-user need analysis, and supply chain impact assessments to evaluate how product characteristics align with clinical workflows and distribution realities. Throughout the methodology, strict criteria guided the inclusion of evidence, emphasizing clinical validity, regulatory compliance, and reproducibility. Sensitivity checks and cross-validation against multiple information streams were performed to reduce bias and enhance confidence in thematic conclusions.

Finally, the research adhered to ethical guidelines for interview conduct and data handling, with anonymization of participant responses where requested. The approach prioritized actionable insights and transparency in assumptions to support decision-makers seeking to apply findings across product development, commercial strategy, and health system partnerships.

Synthesis of key strategic imperatives that connect technological advances, clinical integration, and resilient commercialization to improve glycemic outcomes

In conclusion, the blood glucose monitoring landscape is characterized by rapid technological progress, evolving care models, and complex supply chain dynamics that together shape adoption and value realization. Continuous sensing and improved data connectivity enable clinicians and patients to move from episodic measurement toward proactive, trend-based management. At the same time, decentralized care delivery and remote monitoring require new approaches to reimbursement, clinician workflow integration, and patient education. These converging forces create opportunities for stakeholders who align product design, channel strategy, and evidence generation with real-world clinical needs.

Tariff and trade developments have underscored the necessity of supply chain agility and regional diversification to maintain product availability and cost stability. Segmentation insights reveal that therapeutic application, end-user setting, product type, and distribution channel each demand tailored offerings and engagement models. Regionally, varied payer environments and healthcare infrastructures necessitate differentiated commercialization strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Ultimately, organizations that integrate clinical validation, payer collaboration, and operational resilience into their strategic planning will be best positioned to deliver improved glycemic outcomes and capture long-term value. The recommendations outlined here provide a pragmatic starting point for executives seeking to prioritize investments and partnerships in the evolving monitoring ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of continuous glucose monitoring data with electronic health records platforms
  • 5.2. Emergence of non-invasive optical glucose sensing devices leveraging near infrared technology
  • 5.3. Adoption of AI-driven predictive analytics tools for personalized glycemic trend forecasting
  • 5.4. Growing partnerships between CGM manufacturers and telehealth service providers worldwide
  • 5.5. Expansion of subscription-based glucose monitoring services with remote patient monitoring
  • 5.6. Implementation of interoperable sensor-to-insulin pump communication standards for automation
  • 5.7. Development of pediatric and geriatric specific glucose sensors with lower sample volume requirements

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Glucose Monitoring Market, by Application

  • 8.1. Gestational Diabetes
  • 8.2. Type 1 Diabetes
  • 8.3. Type 2 Diabetes

9. Blood Glucose Monitoring Market, by End User

  • 9.1. Ambulatory Care
  • 9.2. Diagnostic Laboratories
  • 9.3. Home Care
  • 9.4. Hospitals

10. Blood Glucose Monitoring Market, by Product Type

  • 10.1. Continuous Glucose Monitoring Systems
    • 10.1.1. Intermittently Scanned Systems
    • 10.1.2. Real Time Continuous Systems
  • 10.2. Self Monitoring Devices
    • 10.2.1. Control Solutions
    • 10.2.2. Glucose Meters
    • 10.2.3. Lancing Devices
    • 10.2.4. Test Strips

11. Blood Glucose Monitoring Market, by Distribution Channel

  • 11.1. Hospitals Clinics
  • 11.2. Online Retailers
  • 11.3. Pharmacies

12. Blood Glucose Monitoring Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Glucose Monitoring Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Glucose Monitoring Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Diagnostics International AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Dexcom, Inc.
    • 15.3.4. LifeScan, Inc.
    • 15.3.5. Ascensia Diabetes Care Holdings AG
    • 15.3.6. Medtronic plc
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. Nova Biomedical Corporation
    • 15.3.9. Nipro Corporation
    • 15.3.10. Sinocare, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD GLUCOSE MONITORING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD GLUCOSE MONITORING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD GLUCOSE MONITORING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY INTERMITTENTLY SCANNED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REAL TIME CONTINUOUS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTROL SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY LANCING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BLOOD GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 264. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 265. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 266. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 267. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. GCC BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY SELF MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS BLOOD GLUCOSE MONITORING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. G7 BLOOD GLUCOSE MONITORING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-20